Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors
暂无分享,去创建一个
[1] O. Lockridge,et al. Complete amino acid sequence of human serum cholinesterase. , 1987, The Journal of biological chemistry.
[2] M. Froment,et al. Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. , 2007, Biochimica et biophysica acta.
[3] Om Silakari,et al. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. , 2010, European journal of medicinal chemistry.
[4] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[5] C. Geula,et al. Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.
[6] M. Wierdl,et al. Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. , 2007, Journal of medicinal chemistry.
[7] N. Greig,et al. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. , 2006, Journal of Medicinal Chemistry.
[8] N. Harrison. An Introduction to Density Functional Theory , 2002 .
[9] Wei Li,et al. Investigation of binding features: Effects on the interaction between CYP2A6 and inhibitors , 2010, J. Comput. Chem..
[10] Zhihai Liu,et al. Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes , 2010, J. Comput. Chem..
[11] R. Borges,et al. A theoretical antioxidant pharmacophore for resveratrol. , 2009, European journal of medicinal chemistry.
[12] O. Lockridge,et al. Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. , 1999, Chemico-biological interactions.
[13] M. Mesulam,et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.
[14] C. Geula,et al. Butyrylcholinesterase activity in the rat forebrain and upper brainstem: Postnatal development and adult distribution , 2007, Experimental Neurology.
[15] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[16] D. Quinn,et al. Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states , 1987 .
[17] E. Duysen,et al. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. , 2007, Toxicology.
[18] C. Pérez,et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. , 2006, Journal of medicinal chemistry.
[19] A. Cavalli,et al. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. , 2000, Bioorganic & medicinal chemistry.
[20] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[21] S. Brimijoin,et al. Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse , 2000, Journal of neurochemistry.
[22] R. Margalit,et al. Butyrylcholinesterase formulated in liposomes , 1999, Biotechnology and applied biochemistry.
[23] M. Mesulam,et al. Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.
[24] H. Mehrani. Protective effect of polyurethane immobilized human butyrylcholinesterase against parathion inhalation in rat. , 2004, Environmental toxicology and pharmacology.
[25] A. Çokuğraş,et al. Butyrylcholinesterase : Structure and Physiological Importance , 2003 .
[26] D. O'Connor,et al. The cholinesterases: analysis by pharmacogenomics in man. , 2008, Chemico-biological interactions.
[27] N. Cutler,et al. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. , 2002, Clinical neuropharmacology.
[28] E. Begg,et al. Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice , 2006, Pharmacological Reviews.
[29] C. Venkatachalam,et al. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.
[30] J. Sussman,et al. Structure and functions of acetylcholinesterase and butyrylcholinesterase. , 1993, Progress in brain research.
[31] Sugunadevi Sakkiah,et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. , 2010, European journal of medicinal chemistry.
[32] M. Vitorović-Todorović,et al. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. , 2010, Bioorganic & medicinal chemistry.
[33] F. Vallette,et al. Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.
[34] O. Lockridge,et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. , 2008, Journal of medicinal chemistry.
[35] Yvain Nicolet,et al. Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.
[36] S. Sakkiah,et al. Identification of critical chemical features for Aurora kinase-B inhibitors using Hip-Hop, virtual screening and molecular docking , 2011 .
[37] S. Brimijoin,et al. Predicted Michaelis-Menten Complexes of Cocaine-Butyrylcholinesterase , 2001, The Journal of Biological Chemistry.
[38] Asim Kumar Debnath,et al. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. , 2002, Journal of medicinal chemistry.
[39] Tetsuo Satoh,et al. Structure, function and regulation of carboxylesterases. , 2006, Chemico-biological interactions.
[40] R. K. Guy,et al. Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. , 2007, Journal of medicinal chemistry.
[41] Simone Brogi,et al. Pharmacophore Modeling for Qualitative Prediction of Antiestrogenic Activity , 2009, J. Chem. Inf. Model..
[42] A. Main. Mode of action of anticholinesterases , 1979 .
[43] B. P. Doctor,et al. Bioscavengers for the protection of humans against organophosphate toxicity. , 2005, Chemico-biological interactions.
[44] A. Burgen. The mechanism of action of anticholinesterase drugs. , 1949, British journal of pharmacology and chemotherapy.
[45] E. Duysen,et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.
[46] L. Bartolotti,et al. An Introduction to Density Functional Theory , 2007 .
[47] A. Robitzki,et al. The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′butyrylcholinesterase-DNA study , 2000, Progress in Neurobiology.
[48] E. Giacobini. Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.
[49] Asim Kumar Debnath,et al. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. , 2003, Journal of medicinal chemistry.
[50] E. Perry,et al. CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.